USA - NASDAQ:NMTC - US64130M2098 - Common Stock
The current stock price of NMTC is 0.792 USD. In the past month the price decreased by -14.84%. In the past year, price decreased by -15.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.77 | 215.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.05 | 191.53B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.14 | 149.24B | ||
| SYK | STRYKER CORP | 27.05 | 136.19B | ||
| MDT | MEDTRONIC PLC | 16.4 | 116.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.52 | 51.22B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.41B | ||
| RMD | RESMED INC | 24.94 | 36.03B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.33 | 34.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.46 | 26.31B | ||
| STE | STERIS PLC | 24.71 | 23.21B |
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company is headquartered in Eden Prairie, Minnesota and currently employs 17 full-time employees. The company went IPO on 2012-11-09. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
NEUROONE MEDICAL TECHNOLOGIE
7599 Anagram Dr
Eden Prairie MINNESOTA US
Employees: 17
Phone: 19524261383
NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company is headquartered in Eden Prairie, Minnesota and currently employs 17 full-time employees. The company went IPO on 2012-11-09. The company is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
The current stock price of NMTC is 0.792 USD.
NMTC does not pay a dividend.
NMTC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
NEUROONE MEDICAL TECHNOLOGIE (NMTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
The outstanding short interest for NEUROONE MEDICAL TECHNOLOGIE (NMTC) is 0.12% of its float.
ChartMill assigns a technical rating of 1 / 10 to NMTC. When comparing the yearly performance of all stocks, NMTC is a bad performer in the overall market: 77.1% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to NMTC. While NMTC seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NMTC reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 67.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.33% | ||
| ROE | -65.26% | ||
| Debt/Equity | 0.13 |
8 analysts have analysed NMTC and the average price target is 2.27 USD. This implies a price increase of 186.55% is expected in the next year compared to the current price of 0.792.
For the next year, analysts expect an EPS growth of 72.62% and a revenue growth 27.11% for NMTC